Accessible Data Collections for Improved Decision Making in Neuro-Oncology Clinical Trials

Related Experiment Video

Updated: Jun 5, 2026

Generation of Comprehensive Thoracic Oncology Database - Tool for Translational Research
11:18

Generation of Comprehensive Thoracic Oncology Database - Tool for Translational Research

Published on: January 22, 2011

Rifaquat Rahman1, Steffen Ventz2, Robert Redd3

  • 1Department of Radiation Oncology, Dana-Farber/Brigham and Women's Cancer Center, Harvard Medical School, Boston, Massachusetts.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|March 20, 2023
PubMed

Insights

Drug development for rare brain tumors like glioblastoma is slow. The Glioblastoma External (GBM-X) Data Platform uses external patient data to accelerate therapy evaluation and improve drug discovery.

Area of Science:

  • Oncology
  • Neuro-oncology
  • Clinical Trial Design

Background:

  • Drug development for rare and difficult-to-treat solid tumors, such as glioblastoma, faces significant timeline challenges.
  • Leveraging external patient-level data can enhance the efficiency and precision of clinical trial design and analysis.
  • Access to high-quality, external patient-level data is a major hurdle for academic research groups.

Purpose of the Study:

  • To introduce the Glioblastoma External (GBM-X) Data Platform, a resource designed to facilitate the use of external data in neuro-oncology research.
  • To enable investigators to access and analyze existing data collections for improved clinical trial planning and execution.
  • To accelerate the evaluation of novel therapies for glioblastoma and other rare tumors.

Main Methods:

  • Development of the Glioblastoma External (GBM-X) Data Platform.
  • Facilitation of data collection, integration, and analysis for neuro-oncology research.
  • Establishment of a collaborative framework for ongoing data growth and updates.

Main Results:

  • The GBM-X platform provides an accessible process for utilizing external data.
  • It enables contextualization of single-arm trials and improves inference on treatment effects.
  • The platform is designed to foster collaboration and continuous data expansion.

Conclusions:

  • The GBM-X Data Platform offers a valuable resource to accelerate drug discovery for rare and challenging tumors.
  • It serves as a model for leveraging external data to improve the efficiency of oncology clinical trials.
  • Collaboration and data sharing are crucial for advancing therapeutic development in neuro-oncology.

More Related Videos

Performing Data Mining And Integrative Analysis Of Biomarker in Breast Cancer Using Multiple Publicly Accessible Databases07:41

Performing Data Mining And Integrative Analysis Of Biomarker in Breast Cancer Using Multiple Publicly Accessible Databases

Published on: May 17, 2019

Hydrogel Arrays Enable Increased Throughput for Screening Effects of Matrix Components and Therapeutics in 3D Tumor Models10:49

Hydrogel Arrays Enable Increased Throughput for Screening Effects of Matrix Components and Therapeutics in 3D Tumor Models

Published on: June 16, 2022

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.0K
Clinical Trials01:16

Clinical Trials

Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
6.9K
Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
3.1K
Cancer Survival Analysis01:21

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
407